Biogen is opening up its checkbook again to get its hands on innovative approaches to some brain disorders that have proven especially recalcitrant to new types of treatment.
The Cambridge, MA-based neuroscience drug developer is paying gene editing company Sangamo Therapeutics (NASDAQ: SGMO) $350 million up front in a collaboration on potential one-time treatments for neurodegenerative conditions including Alzheimer’s and Parkinson’s diseases.
The “ambitious and expansive” collaboration will leverage gene-editing technology developed by Brisbane, CA-based Sangamo, which uses so-called zinc finger proteins to target and modify certain genes tied to a specific disease, and Biogen’s extensive experience in neuroscience drug… Read more »
UNDERWRITERS AND PARTNERS
